Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
2005

Tamoxifen's Role in Breast Cancer Prevention

Sample size: 13338 publication Evidence: moderate

Author Information

Author(s): Laura J Esserman, Elissa M Ozanne, Mitch Dowsett, Joyce M Slingerland

Primary Institution: University of California San Francisco Medical Center

Hypothesis

Can tamoxifen reduce the risk of both ER+ and ER- breast cancers and promote the transformation of ER+ cancers to ER- cancers?

Conclusion

Tamoxifen may promote the development of ER- cancers from ER+ precursors.

Supporting Evidence

  • Tamoxifen reduced the incidence of ER+ tumors by 69% in the BCPT trial.
  • 44% of contralateral cancers in women over 50 who received tamoxifen were ER-.
  • The model predicts a transformation rate of approximately 20% of ER+ tumors to ER-.

Takeaway

Tamoxifen might help prevent some types of breast cancer, but it could also cause some cancers to change from one type to another.

Methodology

Data from the Breast Cancer Prevention Trial (BCPT) and Multiple Outcomes of Raloxifene (MORE) were analyzed to assess tamoxifen's effects on ER+ and ER- tumors.

Potential Biases

Potential biases may arise from the selection of trial participants and the retrospective nature of data analysis.

Limitations

The study relies on data from previous trials, which may not fully capture the effects of tamoxifen in all populations.

Participant Demographics

The study included high-risk postmenopausal women aged 35 years or older.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/bcr1342

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication